United Therapeutics Files 8-K

Ticker: UTHR · Form: 8-K · Filed: Jan 13, 2025

Sentiment: neutral

Topics: corporate-disclosure, financial-reporting

Related Tickers: UTHR

TL;DR

UTHR filed an 8-K on Jan 13, 2025, with basic company info and financial docs.

AI Summary

United Therapeutics Corporation filed an 8-K on January 13, 2025, reporting under Regulation FD and including financial statements and exhibits. The filing details the company's principal executive offices located at 1000 Spring Street, Silver Spring, MD 20910, and its telephone number (301) 608-9292. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing provides an update on United Therapeutics Corporation's regulatory disclosures and financial reporting, which is important for investors to stay informed about the company's official communications.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report under Regulation FD and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 13, 2025.

Where are United Therapeutics Corporation's principal executive offices located?

United Therapeutics Corporation's principal executive offices are located at 1000 Spring Street, Silver Spring, MD 20910.

What is the telephone number for United Therapeutics Corporation?

The telephone number for United Therapeutics Corporation, including area code, is (301) 608-9292.

In which state was United Therapeutics Corporation incorporated?

United Therapeutics Corporation was incorporated in Delaware.

Filing Stats: 592 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-13 08:57:57

Key Financial Figures

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On January 13, 2025, United Therapeutics Corporation intends to provide an overview and update on the company's business during a presentation and Q&A session at the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will include the slides furnished as Exhibit 99.1 hereto and incorporated herein by reference. These slides will also be posted to the United Therapeutics website at https://ir.unither.com/events-and-presentations. As previously announced, the presentation will take place on January 13, 2025, from 2:15 p.m. to 2:55 p.m., Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 30 days. The information in this Item 7.01 and the related Item 9.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act as amended, regardless of any general incorporation language in such filing.

01

Item 9.01. Exhibits (d) Exhibits Exhibit No. Description of Exhibit 99.1 Investor presentation dated January 13, 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UNITED THERAPEUTICS CORPORATION Dated: January 13, 2025 By: /s/ Paul A. Mahon Name: Paul A. Mahon Title: General Counsel 3

View on Read The Filing